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1. INTRODUCTION 
Non alcoholic fatty liver disease is increasingly being recognised 
as a major cause of liver related morbidity and mortality, because of its 
potential to progress to cirrhosis and liver failure. NAFLD  is deposition 
of fat in the liver of a non-alcoholic subject, a condition which may 
progress to end stage liver disease. (1) 
NAFLD  is an extremely common liver disease in the United States 
(USA), affecting approximately 20% of the adult population. In different 
countries, its prevalence  is 10-24% of the general population. Amongst 
the obese persons, the prevalence rises to 57-74% and 25-75% among 
obese diabetics. Accordingly, NASH is considered as the third 
commonest cause of liver disease after alcohol abuse and hepatitis 
C.Patients with Diabetes mellitus have an increased risk of developing 
the spectrum of non alcoholic fatty liver disease (NAFLD)  
manifestations ranging from simple steatosis, non alcoholic 
steatohepatitis, hepatic fibrosis, cirrhosis and liver failure. Furthermore 
Diabetes mellitus with NAFLD  have three times high mortality 
compared to non-diabetic NAFLD. 
             NAFLD fibrosis score is non invasive predictive score for hepatic 
fibrosis which includes six parameters and categorised into three groups 
based on the scores.F0-F2= <-1.455, Intermediate= -1.455-0.675,F3-
F4=>0.675. 
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2.AIM OF THE STUDY 
 
1. To categorize the Type 2 diabetic patients into four groups-obese, 
non-obese, ultrasonographic presence and absence of hepatic 
steatosis. 
 
2. To analyse the risk of hepatic fibrosis in these patients using 
NAFLD FIBROSIS SCORE. 
 
3. To correlate the stage of fibrosis by fibro scan in group of patients 
with high NAFLD score. 
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3.REVIEW OF LITERATURE 
Nonalcoholic fatty liver disease (NAFLD) is a broader term with a 
spectrum including patients with simple steatosis, steatohepatitis that can 
progress to cirrhosis liver and even hepatocellular carcinoma.(1)(2). In 
1980, Ludwig et al(3) described the term NASH as a form of liver injury 
that was histologically consistent with alcoholic hepatitis but occurred in 
obese, diabetic females, who denied alcohol use. The prevalence of 
NAFLD and NASH in the general population is estimated to be between 
10%-24% and between 1%- 5%, respectively. There is a direct correlation 
between body mass index (BMI) and prevalence and severity of NAFLD. 
The prevalence of NAFLD increases to 57.5% to 74% in obese persons 
and 90% in morbidly obese persons.(4)(5)(6).In India prevalence of 
NAFLD is around 9% to 32% of general population.(7)(8) 
 
NAFLD not only affects the liver, it is a multisystem disease 
affecting extra-hepatic organs and regulatory pathways. It increases risk 
of type 2 diabetes mellitus, cardiovascular and cardiac diseases, chronic 
kidney disease and causal link in sleep apnea, colorectal cancers, 
osteoporosis, psoriasis and various endocrinopathies like polycystic ovary 
syndrome. 
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 Most patients with NAFLD are asymptomatic and may have 
elevation of liver enzymes which is noted incidentally in biochemical 
investigations. Alanine amino transferase and as partate amino transferase 
are usually elevated, but these levels do not reliably correlate with hepatic 
injury, inflammation or cirrhosis in NAFLD. 
 
3.1.NATURAL HISTORY OF NAFLD: 
 About 90% of Patients with  NAFLD have simple steatosis and  
therefore no increase in mortality (9)(10), approximately 10-30% patients 
have NASH (Non Alcoholic Steatohepatitis) which is associated with 
hepatocellular injury and inflammation.25-40% of patients with NASH 
will develop progressive fibrosis and cirrhosis and end stage liver 
disease.(11)(12)(13).Recent  data  states that 28% of patients have 
progression on histological examination, 59% have no change, and  
13%  may have improvement. Matteoni et alretrospectively determined 
the histological and/or clinical outcome of 98 patients with the whole 
spectrum of NAFLD from simple steatosis through NASH to cirrhosis.  
 
 After a median 8-year follow up, 25% of individuals with evidence 
of hepatocyte necrosis with or without Mallory’s hyaline or fibrosis, 
either already had cirrhosis on index biopsy or progressed to cirrhosis. 
This compared with only 3.4%of patients with simple steatosis with or 
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without non-specific inflammatory changes. These observations indicate 
that NAFLD patients without NASH have a benign prognosis.(14) 
 
The development of cirrhosis due to NASH is associated with a 
poor prognosis. 10-year mortality rate is 20% for subjects with  
Child-Pugh A disease and 45% will decompensate within 10 years of 
diagnosis.(15)Patients with cirrhosis  due to NASH are at significant risk 
of developing hepatocellular carcinoma.(16) 
 
3.2.RISK FACTORS OF NAFLD: 
3.2.1.AGE: 
Higher risk is associated with increasing age of the patient. 
 
3.2.2.METABOLIC SYNDROME: 
Metabolic syndrome is independent predictor of fibrosis.70-90% of 
patients with NAFLD  have metabolic syndrome. Insulin resistance is a 
key mediator between NAFLD and metabolic syndrome (17).Any three 
of the following features is diagnosed as metabolic syndrome. 
 
a. Central obesity –   Waist circumference >94cm for men and >80cm 
for women. 
b. Impaired fasting glucose -      >5.6 mmol/L or on treatment. 
c. Hypertriglyceridemia      -      >1.7 mmol/l or on treatment 
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d. Low HDL cholesterol       -     <1.0 mmol/l for men or on treatment 
<1.3 mmol/l for women or on treatment 
e. Hypertension     - >135/85 mm Hg or on treatmernt 
 
3.2.3.GENDER: 
NAFLD is more common in men compared to women, but 
progression to advanced fibrosis is higher in women compared to 
men.(18)(19) 
 
3.2.4.ETHNICITY: 
NAFLD risk is higher in Hispanics  population and lowe in black  
population.(20) 
 
3.2.5.DIETARY FACTORS:  
Diet containing high cholesterol and saturated fats, high fructose  
intake, low carbohydrates increases the risk of NAFLD(21)(22).  
Caffiene may be protective in some patients.(23) 
 
3.2.6.OBSTRUCTIVE SLEEP APNOEA: 
         It increases the risk of NAFLD.(24)(25) 
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3.2.7. GENETIC FACTORS: 
 
          Patatin –like phospholipase domain- containing 3 (PNPLA3). 
(25)(26)(27) PNPLA3 lysophosphatidic acid acyltransferase activity 
could also contribute to altered plasma triacylglycerol composition and 
concentration. 
 
3.2.8.NUTRITIONAL FACTORS: 
Obesity, rapid weight loss, total parenteral nutrition, prolonged 
starvation are attributed as causal factors in NAFLD. 
 
3.2.9.DRUGS: 
Corticosteroids, Amiodarone, Bleomycine, Tetracycline,  
Methotrexate, Perhexiline, Diltiazem, nifedipine , Tamoxiphen. 
 
3.2.10.CHEMICALS: 
Hydrocarbons and yellow phosphorous are associated with fatty 
liver. 
 
3.2.112.SURGERY: 
Surgeries like  Jejunoileal bypass,extensive small bowel loss, 
gastropexy are associated with fatty liver. 
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3.3.ETIOPATHOGENESIS OF NAFLD/NASH: 
The pathogenesis of the NASH is not completely understood.The 
conditions associated with NAFLD include nutritional abnormalities, 
metabolic disorders, drugs, chemicals and surgery as mentioned 
above.Initially there is steatosis which later, after a series of events, may 
progress on to inflammation and fibrosis and finally to cirrhosis and end 
stage liver disease.(28)(29)(30) NASH may be considered as  a two hit 
process, first hit is accumulation of the fat  and the second hit is 
hepatocellular injury in the fatty liver .(30)The first hit of steatosis occurs 
because of the imbalance between the fatty acid uptake, its oxidation, 
esterification and export as very low-density lipoprotein (VLDL) from 
the hepatocytes. Insulin resistance is the most important key 
factor(28)((30)(31)which leads to increase in lipolysis and increased 
uptake of fatty acids by hepatocytes. 
 
Hyperinsulinemia  which occurs as  result of insulin resistance 
increases the intrahepatocytic fatty acids by increasing the glycolysis and 
decreasing the apolipoprotein B-100 and resulting in decreased export as 
VLDL. The end result is the increase in fatty acids and triglycerides in the 
hepatocytes leading to steatosis or fatty liver.  
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The free fatty acids in the hepatocytes acts as reactive oxygen 
species and  increases the mitochondrial β-oxidation and  cytochrome  
P-450 4A and cytochrome P450 2E1 levels.The  mitochondrial oxidative 
stress leads to the second hit from steatosis to steatohepatitis and fibrosis 
by three main mechanisms, namely (i) lipid peroxidation, (ii) cytokine 
induction, and (iii) Faslig and induction.(28)(30) 
 
(i). Lipid peroxidation causes oxidative destruction of 
polyunsaturated fatty acids of cellular membranes. The cytotoxic 
products  which are released due to lipid peroxidation  impair cellular 
functions including nucleotide and protein synthesis leading to cell death, 
formation of Mallory hyaline, promoting tissue inflammation, activation 
of stellate cells and collagen synthesis.(28) 
 
(ii). Cytokines like IL-1, IL-6 IL-8 and tumor necrosis factor-α 
(TNF-α) plays an important role in the pathogenesis of liver injury in 
patients with NASH.(31) 
 
IL-1, IL-6, and IL-8 are pro-inflammatory cytokines and IL-10 and 
IL-12 are anti-inflammatory cytokines. TNF-α, TGF-β, interleukin-8 and 
cause chemotaxis, formation of Mallory hyaline and synthesis of collagen 
by activated stellate cells.  
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TNF–αdownregulates insulin-induced phosphorylation of insulin 
receptor substrate 1 and reduces the expression of the insulin-dependent 
glucose transport molecule Glut 4 and thus contributes towards insulin 
resistance which is thought to be the major mechanism in the 
pathogenesis of NASH.(31)(32) 
 
TNF-α is derived from adipose tissue in the absence of active 
infections or inflammatory conditions. Plasma levels of TNF-αalso 
correlates with body fat mass and is associated with insulin resistance. 
(37) TNF-α knockout mouse also  fails to develop insulin resistance after 
induction of obesity suggests its crucial role in the pathogenesis of insulin 
resistance.(38)The oxidative stress  leads to the IkKβ activation and  
release of TNF- α and insulin resistance, which ultimately leads to 
steatohepatitis
 
(iii). Finally the expression of Fas ligand due to oxidative stress 
leads to fractional killing by interaction with Fas on other hepatocytes. 
 
Other factors that are  involved in the pathogenesis of NASH 
include serum and liver iron,(33)(34)leptin,(35) bacterial overgrowth, 
(36)(37)(38) Saturation of mitochondrial β-oxidation leads to 
peroxisomal oxidation and generation of hydrogen peroxide, which in the 
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presence of increased iron is converted to hydroxyl radicals, thus adding 
to the oxidative stress and further injury.(39) 
 
Leptin, a product of obesity gene regulates the food intake and 
body composition through a central feed back mechanism and is proposed 
to be a key pathophysiological factor for obesity. Leptin leads to hepatic 
steatosis by promoting insulin resistance or by modulating insulin 
signaling in hepatocytes.(34) 
 
Bacterial overgrowth in the gut can cause liver injury by causing 
endotoxemia and release of  cytokines. The mechanisms by which 
intestinal bacteria may increase hepatic oxidative stress include increased 
endogenous production of ethanol and by direct activation of 
inflammatory  cytokines in luminalepithelial cells, and liver macrophages 
or both .(35) 
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FIG 1: The factors like visceral ectopic fat accumulation, adipose tissue 
inflammation, type 2 diabetes and intestinal dysbiosis which promote 
development of progressive liver disease in NAFLD.(Non Alcoholic 
Fatty Liver Disease ) 
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3.4.NAFLD AND DIABETES MELLITUS: 
When imbalance occurs between energy intake and energy 
expenditure, or an intrinsic problem with storing excess energy as lipid 
(triacylglycerol) in adipose tissue depots, lipid occurs in other organs 
throughout the body. Ectopic fat accumulation is defined as lipd 
accumulation in tissues, organs not designed to accumulate e.g., liver or 
omentum other than adipose tissue.(40) 
 
NAFLD is an ectopic fat accumulation which is associated with 
increased secretion of hepatokines (41), increased gluconeogenesis, 
decreased glycogen synthesis and inhibition of insulin signaling (42)(43).  
Adipose tissue inflammation is crucial in NAFLD pathogenesis and 
evidence suggesting that dysbiosis of the gut microbiota plays a  major 
key role in development and progression of NAFLD. This is mailnly 
because of the increased intestinal absorption of  bacterial products, such 
as short-chain fatty acids (e.g., butyrate, propionate and acetate), 
lipopolysaccharide and endotoxins.  
 
Mechanisms involved in the pathogenesis of insulin resistance and 
inflammation in NAFLD is explained briefly.Although obesity is strongly  
associated with hepatic steatosis,excess body fat accumulation is not ‘sine 
qua non’ for developing NAFLD. In fact, patients with lipodystrophy 
have marked insulin resistance and commonly develop hepatic steatosis 
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and T2DM, strongly suggesting that it is not body fat mass per se that is 
important, but it is adipose tissue dysfunction that is a key contributor to 
the pathogenesis of NAFLD (46).  
 
Specifically, increased free fatty acid (FFA) fluxes from the 
adipose tissue pool increase the availability of long-chain fatty acyl-CoAs 
for hepatic lipid accumulation, particularly in physically inactive 
individuals(44), and evidence is accumulating that hepatic lipid 
accumulation is capable of causing hepatic/peripheral insulin resistance 
and promoting hepatic inflammation (40)(44).Expansion of peripheral 
adipose depots provides buffering capacity that may protect the liver from 
the excessive FFA fluxes that promote hepatic  lipid accumulation. 
Within hepatocytes, long-chain fatty acids  are esterified with glycerol-3-
phosphateto form mono-acylglycerols, di-acylglycerols and tri-
acylglycerols. 
 
Lipid synthesis is very important in causing ‘resistance’within the 
hepatic  insulin signaling pathway (47), promoting hepatic inflammation 
(48) and increasing risk ofprogressive liver disease that occurs with 
NASH. In the liver ceramides can accumulate into the cells via three 
main routes: 1) the hydrolysis of the membrane phospholipid 
sphingomyelin, which is coordinated by the  enzyme sphingomyelinase; 
2) de novo synthesis from long chain fatty acids such as palmitate and 
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serine; and 3) a ‘salvage’ pathway that utilizes sphingosine and forms 
ceramide (54)(55). Ceramide plays an important role in  causing insulin 
resistance.(55) 
 
Hepatic lipids that are not esterified also induce endoplasmic 
reticulum stress, leading to the activation of c-Jun N-terminal kinases and 
NF-jB (55),which are two major regulators of inflammatory pathways 
that also inhibit phosphorylation of insulin receptor substrate-1 (IRS-1) 
(56), potentially aggravating hepatic insulin resistance and increasing 
intra-hepatic cytokine production . Synthesis of lipids such as di acyl 
glycerol (DAGs) is intimately related to inflammatory pathways, and 
DAGs may also contribute to hepatic production of inflammatory 
cytokines [e.g.,tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6)], 
and procoagulant factors [e.g., factor VIII, plasminogen activator 
inhibitor-1 (PAI-1)].  
 
 Intestinal microbiota dysbiosis  may affect other hepatic lipid  
pathways, such as those involving bile acid metabolism,consequently 
increasing hepatic inflammation and fibrosis,and resulting in an increased 
risk of developing cirrhosis and HCC. 
 
Till date, it is unclear whether improvements in NAFLD may 
ameliorate risk of T2DM or improve glycaemic control in people with 
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NAFLD who have developed T2DM, but it is plausible that resolution of 
liver fat and improvements in liver lipid metabolism might modify the 
risk of T2DM via a liver-specific effect. Such a liver-specific effect could 
be mediated by alteration in the secretion of multiple hepatokines or 
inflammatory cytokines that influence risk of diabetes. In NAFLD, 
secretion of diabetogenic hepatokines, such as retinol binding protein 
(RB)-4, fetuin-A, fibroblast growth factor (FGF)-21; or inflammatory 
biomarkers such as C-reactive protein (CRP), TNF-a and IL-6 (57)may 
directly affect risk of incident T2DM by adversely affecting hepatic 
gluconeogenesis,glycogen synthesis and insulin signaling (58). 
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FIG 2 : Mechanism of insulin resisratance, adipose tissue inflammation 
and role of hepatokines, adipokines in NAFLD. 
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3.5.NAFLD AND METABOLIC SYNDROME: 
Metabolic syndrome is characterized by the presence of insulin 
resistance  in association with other metabolic abnormalities like obesity, 
diabetes, hypertriglyceridemia and hypertension. Common associations of 
 NAFLD, such as hypertension, hyperuricemia, and polycystic ovary 
syndrome are also common to metabolic syndrome. 
 
The chances of individual having NAFLD and NASH increase 
with increasing body weight, with 70-80% of obese individuals having 
NAFLD and  15-20% having NASH. Conversely 30-100% of NASH 
patients have obesity.  
 
Truncal obesity  is more commonly associated with NASH, also 
with causal link  to diabetes and hypertension. In morbidly  obese 
patients, the risk of liver disease progressively increases with the number 
of features of metabolic syndrome.(59)(60)Metabolic syndrome was 
present in 22% of Indian patients with NASH.(61) 
 
3.6.NAFLD AND CARDIOVASCULAR DISEASES: 
Non alcoholic fatty liver disease is associated with increased risk 
and morbidity for cardiovascular diseases and risk further increases in 
Type 2 diabetus mellitus. In addition pateints with non alcoholic 
steatohepatitis have further increased risk of cardiovascular diseases. 
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Myocardial metabolism is primarily affected in NAFLD. By 
cardiac magnetic resonance imaging (MRI), Perseghin et al. reported that 
nonobese, nondiabetic, normotensive, young individuals with  
NAFLD had impaired myocardial energy metabolism (i.e., a lower 
phosphocreatine/adenosine triphosphateratio, as measured by 31P-
magnetic resonance spectroscopy  and excessive fat accumulation in the 
epicardial area compared with control subjects without NAFLD. 
Interestingly, these myocardial metabolic alterations were detected 
despite normal left ventricular (LV) morphological features and systolic 
and diastolic functions (62). Lautamaki et al.(63)and Rijzewijk et al. 
(64)found that T2DM patients with higher intra-hepatic fat content on 
1H-MRS had increasedmyocardial insulin resistance and decreased 
myocardial perfusion compared with those with lower intra-hepatic fat 
content, additionally, myocardial insulin resistance was more severe 
among those with higher intra-hepatic fat content , those with higher 
intra-hepatic fat content had significantly higher myocardial fat content.  
 
Interestingly, in this study cardiac steatosis was astrong predictor 
of LV diastolic dysfunction.(65) NAFLD with increased  liver 
transaminases is an  independent  risk factor for atrial fibrillation in the 
Framingham Heart Study cohort (66).  
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Asimilar link was found between elevated serum liver enzymes and 
AF risk was shown in a larger prospective community-based study of 
9333 subjects with a  follow up for 12 years (67). NAFLD is also 
independently linked with prolonged QTc interval which is a powerful 
predictor of ventricular arrhythmias and sudden cardiac death and the 
presence of  progressive aortic valve sclerosis. All these factors 
contributes to increased cardiovascular risk in NAFLD patients.(68)(69) 
 
3.7.NAFLD AND CHRONIC KIDNEY DISEASE:- 
 The prevalence of chronic kidney disease is increased among 
patients with non alcoholic fatty liver disease with or without diabetes 
mellitus. The estimated glomerulation filtration rate and overt proteinuria 
is measured in patients with chronic kidney disease.(70)The severity of 
NAFLD varied upon the stages of chronic kidney disease. The patients 
had fatty kidney and increased renal sinus fat volume caused structural 
and functional derangements in the kidneys.(71) 
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FIGURE 3: The link between NAFLD and cardiovascular and kidney  
structural and functional changes. 
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3.8. CLINICAL FEATURES: 
1.SYMPTOMS:- 
 Asymptomatic (30-40%) 
 Right upper subcostal pain or discomfort (30-40%) 
 Fatigue (<10%) 
 Pedal edema 
 Gastrointestinal bleeding 
 Abdominal distension  
 
2. SIGNS:- 
 Normal examination 
 Increased body mass index (BMI) 
 Increased waist circumference (truncal obesity) 
 Stigmata of chronic disease if cirrhosis is present. 
 Lipomatosis/lipoatrophy /lipodystrophy 
 Hepatomegaly (50-70%) 
 Splenomegaly 
 Ascites 
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3.9. INVESTIGATIONS: 
3.9.1. BIOCHEMICAL : 
i. Raised aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) - up to 4-5 times elevation 
ii. Alkaline phosphatase - up to 2 times elevation 
iii. AST/ALT - majority <1; >1 may indicate cirrhosis 
iv. Bilirubin - elevated in late stage 
v. Albumin - decreased in late stage 
vi. Prothrombin time - prolonged in late stage 
vii. Serum markers of iron overload - ~25% but do not indicate  
hemochromatosis.            
viii. Anti-nuclear antibody -  one-third 
 
3.9.2. FIBROSIS SCORES: 
1.NAFLD FIBROSIS SCORE: 
Fibrosis staging is important in all patients with NAFLD to identify 
patients with advanced hepatic fibrosis at risk of liver-related 
complications. Hepatocellular dysfunction and portal hypertension result 
from advancing hepatic fibrosis. This can be noticed in blood 
investigations such as liver function tests (low albumin), full blood count 
(thrombocytopenia) and coagulation profile (prolonged prothrombin 
time). These tests give an indirect measure of fibrosis and act as non-
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invasive markers of fibrosis as they are less cost and are performed in all 
patients with hepatic disease. With increasing hepatic fibrosis, the ALT 
typically falls and the AST remains stable or rises and as a result, the 
AAR (aspartate and alanine amino transferase ratio) increases and can be 
an useful simple method of identifying patients with advanced fibrosis. 
Previous studies identified a cut-off>1 for the AAR as a diagnostic test 
for cirrhosis. (72)(73) 
 
2.BARD SCORE: 
The BARD score  is a simple test using thebody mass index>=28 – 
1 point,  AST/ALT ratio  >=0.8 -2 points and presence of type 2diabetes 
mellitus – 1 point. The score ranges from 0 to 4 points. A score <2 has 
excellent negative predictive value of95–97%, which excludes advanced 
hepatic fibrosis. 
 
However, in a typical NAFLD cohort, a large proportionof patients 
with mild disease have a score of ≥2because of diabetes limiting its utility 
in clinical practice.(74) 
 
3.FIB-4 SCORE: 
The FIB-4 score althoughderived in patients with HIV and 
HEPATITIS B  coinfection, appears to be one of the most essential 
noninvasive tests for diagnosing advanced fibrosis inNAFLD. For stage 
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3–4 fibrosis, a score <1.3 has a90% NPV and a score >2.67 has an 80% 
PPV, with 72% of patients scoring below 1.3 or above 2..Other studies 
have proved that the FIB-4 score is considered slightly better than other 
non-invasive tests in diagnosing advanced fibrosis in NAFLD, including 
in subjects with normal range ALT levels.(75) 
 
4.CK-18: 
Levels of cytokeratin-18 (CK-18)  fragments correlate with the 
magnitude of Hepatocyte apoptosis and predict the presence of NASH( 
non alcoholic  steatohepatitis).Cytokeratins are proteins of keratin 
containing intermediate filaments found in intracytoplasmic cytoskeleton 
of epithelial tissue. Mallory body composed of abnormally 
phosphorylated cross linked keratins like cytokeratin 8 and 18. 
 
5.HAIR SCORE:- 
1. Alanine transaminase (ALT) > 40 IU/l 
2. Insulin resistance (IR) index > 5 
3. Hypertension 
Presence of 2 or all 3 factors predict NASH. 
 
6. BAAT SCORE:- 
1. Age > 50 yrs. 
2. Body mass index (BMI) > 28 kg/m2. 
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3. Triglyceride> 1.7 mmol/l. 
4. Alanine aminotransferase (ALT)> 2-fold rise. 
Presence of none or only 1 factor rules out the possibility of 
fibrosis or cirrhosis. 
 
7.OTHER NON INVASIVE TESTS: 
The Enhanced Liver Fibrosis (ELF) test is a commercialpanel of 
markers of matrix turnover: tissue inhibitor of matrix metalloproteinase 1 
(TIMP1), hyaluronic acid and PIIINP.(76) Fibrotest (FT) is a commercial 
tool of biochemical markers of fibrosis that is prevalently used in France. 
In NAFLD, FT can diagnose advanced hepatic fibrosis withmodest 
accuracy .Using a FT cut-off of 0.30 gives a 90% NPV for advanced 
fibrosis (sensitivity 77%), and a FT cut-off of 0.70 had a 73% PPV for 
advanced fibrosis (specificity 98%).Other scores include Palekar’s 
score,Gholam score,Nippon score and BAAT score.(77) 
 
3.9.3.IMAGING: 
 Ultrasound : 
Findings of hepatic steatosis in ultrasound are  increased 
echogenicity and coarsened echotexture of the .If steatohepatitis has 
progressed  to cirrhosis, a nodular liver surface may be present in addition 
to other fibrotic changes. 
30 
 
 Fibro scan:- 
Fibrotic livers have less elasticity due to the fibrous tissue 
deposition in the hepatic parenchyma. TE (Fibroscan) gives a ‘liver 
stiffness measurement’(LSM) using pulsed-echo ultrasound as a 
surrogate marker of fibrosis. The LSM correlates well with the degree of 
liver fibrosis in a wide range of liver diseases, including NAFLD.(78) 
However, there are multiple drawbacks in using TE in NAFLD.  
Invalid results appear in older patients (>52 years) and those with central 
obesity (BMI >35 kg/m2) or type 2 diabetes. The Fibroscan XL probe has 
been developed for obese patients but is associated with fewer LSM 
failures. 
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 Computed tomography/Magnetic resonance imaging 
A. CT scan findings in NAFLD: 
 Picking up of focal areas of fatty infiltration. 
 Mean CT Hounsfield unit in liver( diffuse hypoattenuation) less 
than that inspleen helps in diagnosis. 
B. MRI findings in NAFLD: 
 Phase contrast imaging gives adequate information about fatty 
infiltration of liver giving very good quantitativeassessment of 
status of disease. 
 Useful for excluding fatty infiltration. 
 On T1-weighted images, there is loss of intensity in  focal areas of 
deposition of fat. So,in early stage of disease ,small lesions are 
readily identifiedon MRI 
 It is more sensitive and specific compared to USG or CTscan, but 
is expensive. 
C. Radionuclide scanning (scintigraphy) studies: 
 With technetium-99m sulphur colloid scanning, focal areas of 
deposition of fat appear as fillingdefects. 
 Radio-xenon has a very high affinity for fat and itremains bound to 
fat and retained in fat. This gives qualitative as well as quantitative 
assessment offat deposition in liver. 
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 ARFI: 
The non-invasive assessment of hepatic fibrosis is acoustic 
radiation force impulse (ARFI). This technique uses conventionalB-mode  
ultrasonography to generate anultrasonic pulse and measurement of the  
response of the livertissue as shear wave velocity. The degree of hepatic  
fibrosis correlates with median velocity measured by ARFI.(79) 
 
3.9.4.LIVER BIOPSY: 
Performing a liver biopsy on every patient with suspected NAFLD 
remains a controversial  area in  practice, and clearly is not a practical 
consideration as a “screening” tool. The general indications for 
performing a liver biopsy in patients with NAFLD are to confirm or 
exclude the diagnosis, diagnose other liver diseases, and to determine 
amounts of damage to the liver for treatment and prognosis. The last 
includes necroinflammatory activity, which is potentially reversible, and 
collagen deposition with varying degrees of remodeling, which is 
potentially less reversible.  The major limitation of liver biopsy is the 
invasive nature of the procedure.(80) Though considered “minimal”,  
liver biopsy is an invasive procedure and can have complications even in 
the ideal clinical conditions, including pain, minor and major bleeding 
(0.3%).(81) 
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 A: Mixed large and small droplet steatosis, single droplet, with 
nucleus pushed to one side, 
 B: Microvesicular steatosis, nuclei in the center with foamy 
cytoplasm, and mega mitochondria  
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 C: Ballooned hepatocytes with flocculent cytoplasm. 
 D: Loss of cytoplasmic expression of keratin 8/18 in ballooned 
hepatocytes,  
 E: Mallory-Denk body 
 F: Mallory-Denk body in blue-green color and dense perisinusoidal 
fibrosis. 
 G: Portal lipogranuloma. 
 H: Mallory-Denk bodies andsatellitosis. 
 I: Delicate perisinusoidal fibrosis. 
  J: Bridging fibrosis. 
 
TREATMENT OF NON ALCOHOLIC FATTY LIVER DISEASE: 
Treatment is aimed at correcting the risk factors for NAFLD, such 
as, medical control of hyperglycemia, and use of lipidlowering agents for  
hypertriglyceridemia, and lifestyle modification and pharmacological 
agents to improve insulin sensitivity. 
 
INSULIN SENSITIZERS:- 
Thiazolidinediones are a class of drugs that stimulate peroxisome 
proliferator activated receptors (PPAR).An insulin-sensitizing 
medication, troglitazone (a thiazolidinedione) is used. 
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LIPID  LOWERING AGENTS: 
Hypertriglyceridemia is associated with NAFLD. Clofibrate and 
gemfibrozil can be used. 
 
PHARMACOLGICAL THERAPY OFFERING HEPATOCYTE  
PROTECTION: 
Ursodeoxycholic acid (UDCA), and the anti-oxidants, betaine and 
vitamin E, have peer-reviewed published data.Other drugs, e.g., lecithin, 
β-carotene, selenium, and Nacetylcysteine. 
 
UDCA:- 
This hydrophilic bile acid with hepatoprotective properties was 
first evaluated in a pilot study, where it was associated with both 
improved liver enzyme levels and a decrease in hepatic steatosis.  
 
Vitamin E (α-Tocopherol):- 
The observation that vitamin E decreases oxidative stress provides 
a rationale For its use in patients with NASH. One uncontrolled trial in 
children with NASH showed that supplementation with vitamin E (400 to 
1200 IU daily) was associated with a significant decline in serum 
aminotransferases. 
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There was a significant improvement in fibrosis scores in the 
NASH patients receiving vitamins compared to baseline but no 
improvement in necroinflammation or ALT. 
 
Betaine:- 
Betaine, a normal component of the metaboliccycle of methionine, 
is a precursor of S-adenosylmethionine, a hepatoprotective factor.  
 Liver Transplantationis the choice of treatment in end stage liver 
disease. 
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4.MATERIALS AND METHODS 
 This study was carried out in Govt Stanley Medical college 
Hospital, Chennai. This is a facility based observational study involved 
the patients who attended medicine and diabetology outpatient 
departments and as  well as inpatients during the study period  of March 
2017-September 2017. 
 
STUDY DESIGN:OBSERVATIONAL STUDY 
DATE OF APPROVAL BY ETHICAL COMMITTEE:FEBRUARY 
2017 
 
PLACE OF STUDY: 
 DEPARTMENT OF INTERNAL MEDICINE,GOVERNMENT 
STANLEY MEDICAL GENERAL HOSPITAL,CHENNAI. 
 
SELECTION OF CASES: 
 Diabetic outpatients and inpatients  attending our institiute. 
 
SAMPLE SIZE: 
 A total of 100 patients of diabetes mellitus who attended the 
outpatients department and admitted in medicine wards. 
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4.1 .INCLUSION CRITERIA: 
 1.All patients diagnosed as  Type 2 Diabetes Mellitus by WHO 
criteria. 
 2.Age more than 18 years. 
 
4.2.EXCLUSION CRITERIA: 
1. Patients less than 18 years and more than 85 years. 
2. Patients with history of alcohol intake more than 30 grams/day in 
males and more than 20 grams/day in females. 
3. Patients with history of jaundice,Hepatitis B and C infection. 
4. Patients with  history of following drug intake such as steroids, 
synthetic Oestrogens,calcium channel blockers, amiodarone, 
valproic acid, heparin, antiviral agents. 
 
4.3.METHODOLOGY: 
 Patients were made to understand in their local language and 
informed consent was obtained before collecting data and subjecting to 
investigations. 
 Patients were  divided into  four groups -obese group and non obese 
group  according to WHOBMI criteria.BMI calculated by Quetelet index 
–  Weight in kilograms / height in m2.Ultrasonographic presence and 
absence of hepatic fibrosis. 
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 OBESE GROUP- BMI > 30kg/m2 
 NON OBESE GROUP – BMI <29.9 kg/m2. 
 
ASSESMENT OF PARAMETERS: 
1.Age 
2.Diabetes mellitus 
3.Body mass index (BMI) 
4.Aspartate aminotransferase level. 
5.Alanine aminotransferase level. 
6.Platelet count. 
  
FORMULA OF NAFLD FIBROSIS SCORE: 
 -1.675+ 0.037 * AGE (years) +0.094 * BMI (kg/m2) +1.13 
* IFG/ DIABETES ( yes =1,no=0) +0.99 * AST/ALT ratio -
0.013 * platelet (* 109 /l) -0.66 * albumin (g/dl). 
 
EXPLANATION OF RESULT: 
 NAFLD SCORE    <-1-455 = F0 –F2 (LOW RISK) 
 NAFLD SCORE    -1.455- 0.675 = indeterminate score 
 NAFLD SCORE     >0.675 = F3- F4.  (HIGH RISK) 
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5.OBSERVATION 
100patients  of Type 2 diabetes mellitus  who attended general 
medicine and diabetology outpatient and inpatient departments in 
government stanley medical college during the period of march 2017 to 
september 2017 was studied and data collected and interpreted. 
 
5.1.PATIENT  CHARACTERISTICS: 
5.1.1.PATIENT PROFILE: 
Out of 100 patients,40 patients were male and 60 patients were 
females and patients were grouped into obese, non-obese, 
ultrasonographic presence of hepatic steatosis and ultrasonographic 
absence of hepatic steatosis. 
 
 Out of 100 patients, 57 patients (57%) were  in obese group and 43 
patients (43%)in non- obese group. 
 
34 patients (59.6%)  had ultrasonographic evidence of hepatic 
steatosis in the obese group.3 patients (6.9%) had ultrasonographic 
evidence of hepatic steatosis in non obese group. 
 
23 patients (40.4%) had no ultrasonographic evidence of hepatic 
steatosis in obese group. 40 patients (93%) had no ultrasonographic 
evidence of hepatic steatosis in non-obese group. 
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5.2.PARAMETERS STUDIED: 
5.2.1.NAFLD FIBROSIS SCORE: 
Non alcoholic fatty liver disease fibrosis score was applied to all 
patients in both obese and non obese group and categorised into high risk, 
intermediate risk and low risk. 
 
Accordingly 20 patients(35%) had high risk in obese group, 1 
patient (0.2%) had high risk in non obese group. 
 
21 patients (36%) had intermediate risk in obese group and 6 
patients (13.9%) had intermediate risk in non obese group. 
 
16 patients (28%) had low risk in obese group and 36 patients 
(83.7%) had low risk in non obese group. 
 
 
5.2.2.FIBRO SCAN: 
Non  invasive fibroscan/ elastography was done to calculate the 
liver stiffness in patients with non alcoholic fatty liver disease and high 
NAFLD score. 
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Accordingly 20 patients of obese group had high risk of hepatic 
steatosis and fibro scan was done for the patients. 
 
4 patients (20 %) had F0-F1 stage of fibrosis in fibro scan( 
according to METAVIR staging) 
13 patients (65%) had F2-F3 stage of fibrosis. 
3 patients (15%) had  F4 stage of fibrosis. 
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TABLE 1: AGE RANGE OF STUDY POPULATION 
Agerange 
 
Frequency Percent 
 Upto 35 yrs 6 6.0 
36 - 45 yrs 27 27.0 
46 - 55 yrs 32 32.0 
56 - 65 yrs 26 26.0 
Above 65 yrs 9 9.0 
Total 100 100.0 
 
 
TABLE 2: STATISTICS OF AGE 
AGE 
N Valid 100 
Mean 50.83 
Median 50.00 
Std. Deviation 10.431 
Range 48 
Minimum 26 
Maximum 74 
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FIGURE 1: PIE CHART REPRESENTING THE PERCENTAGE 
OF OBESE AND NON OBESE GROUP IN STUDY POPULATION 
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FIGURE 2: PERCENTAGE OF STUDY POPULATION WITH 
USG EVIDENCE OF FATTYLIVER 
AND NO FATTY LIVER 
 
 
 
 
 
 
 
 
 
 
 
  
37%
63%
USG
Fatty Liver Non Fatty liver
49 
 
 
 
 
FIGURE 3: PERCENTAGE OF STUDY POPULATION HAVING 
EVIDENCE OF FATTY LIVER IN BOTH GROUPS. 
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FIGURE 4: PERCENTAGE OF POPULATION WITH NO 
EVIDENCE OF HEPATIC STEATOSIS IN 
ULTRASONOGRAPHY 
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FIGURE 5:-  PERCENTAGE OF STUDY POPULATION WITH 
HIGH, INTERMEDIATE AND LOW RISK IN OBESE GROUP. 
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FIGURE 6 :  STAGE OF FIBROSIS IN FIBRO SCAN  
IN OBESE GROUP. 
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6.DISCUSSION 
 The study was conducted in government stanley medical college 
hospital and the study population was 100 patients. Informed consent was 
obtained from all the patients included in the study. 
 
 All the patients included were Type 2 Diabetes Mellitus patients 
diagnosed by WHO criteria. Study population was subjected to blood 
investigations, ultrasonography and selected patients for fibro scan. The 
data was collected and interpreted and analysed using IBM.SPSS 
statistics software 23.0 Version. To describe about the data descriptive 
statistics frequency analysis, percentage analysis were used for 
categorical variables. 
 
 The study population included 40 males and 60 females. Study 
population categorised to obese and non obese group. 57 % of population 
were in obese group and 43 % in non obese group. 59.6% of  
patients had ultrasonographic evidence of hepatic steatosis in obese group 
and 40.4%  had no ultrasonographic evidence of hepatic steatosis in obese 
group. 
 
 6.9% of patients only had ultrasonographic evidence of hepatic 
steatosis in non obese group and 93% had no evidence of hepatic steatosis 
in non obese group. This shows the significance of body mass index and 
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obesity playing a major role in pathogenesis of non alcoholic fatty liver 
disease. The percentage of patients with fatty liver is  significantly higher 
in obese group than in non obese group.  
 
 The non alcoholic fatty liver disease fibrosis score was calculated in 
all patients of study population and 35% of patients had high risk score in 
obese group compared to only 0.2% in non obese group. 
 
 36% of patients had intermediate risk in obese group compared to 
13.9% in non obese group. 28% had low risk in obese group compared to 
83.7% in non obese group.This showed that obese group had significantly 
higher risk of hepatic fibrosis compared to non obese group in diabetic 
patients. 
 
 When the patients of high risk NAFLD score of both groups 
including 20 patients from obese group and 1 patient from non obese 
group were subjected to fibro scan , the correlation between fibro scan 
and NAFLD score was similar and hence prove  that non invasive tests 
have upcoming role in clinical practise compared to invasive tests like 
liver biopsy  etc.. in  early diagnosis and appropriate management for the 
group of patients with risk factors of non alcoholic fatty liver disease. 
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7. SUMMARY 
          The study was done in 100 patients diagnosed to have Type 2  
diabetes mellitus according to WHO criteria and categorised into  
obese and non obese groups according to Body Mass Index and  
ultrasonography was done to all subjects and categorised into patients 
with hepatic steatosis and no  evidence of hepatic steatosis. Non alcoholic 
fatty liver disease fibrosis score was calculated for all patients and 
divided into three groups with low risk, intermediate and high risk. 
          Fibroscan was done for all patients with high risk NAFLD fibrosis 
score and correlation was studied, and all patients with high score was 
found to have significant stage of fibrosis according to METAVIR 
staging. Non alcoholic fatty liver disease fibrosis score was found  
significant in staging of  hepatic fibrosis and  correlated with fibro scan in 
staging of hepatic fibrosis or liver  stiffness. NAFLD fibrosis score was 
found to be increased in obese patients,  type 2 diabetes mellitus and  
helpful in early diagnosis of NAFLD and early intervention in  
reducing risk factors like hyperglycemia, hypertriglyceridemia, metabolic 
syndrome and reduce complications of NAFLD. 
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FIGURE 1: GENDER DISTRIBUTION IN STUDY POPULATION 
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FIGURE 2: AGE RANGES IN THE STUDY POPULATION. 
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TABLE 1 : MEAN , MEDIAN AND MODE FOR AGE: 
OBSERVATIONS TOTAL MEAN VARIANCE 
STANDARD 
DEVATION 
100.00 5083.00 50.830 108.80 10.43 
MINIMUM 25% MEDIAN MAXIMUM MODE 
26.000 44.000 50.000 74.000 45% 
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FIGURE 3: NAFLD FIBROSIS SCORE IN THE STUDY 
POPULATION 
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TABLE : 2 SEX DISTRIBUTION  
 
SEX 
 
Frequency Percent 
 Male 40 40.0 
Female 60 60.0 
Total 100 100.0 
 
 
TABLE : 3: EVIDENCE OF FATTY LIVER IN OBESE  
AND NON OBESE GROUP. 
 
 OBESE GROUP 
NON OBESE 
GROUP 
FATTY LIVER 34 ( 59.6%) 3 (6.9%) 
NO EVIDENCE 
OF FATTY LIVER 
23(40.4%) 40 (93.1%) 
TOTAL 57 43 
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TABLE 4  : NAFLD SCORE IN OBESE AND NON OBESE GROUP 
NAFLD SCORE OBESE GROUP 
NON OBESE 
GROUP 
HIGH RISK 20  ( 35%) 1 (0.2%) 
INTERMEDIATE 
RISK 
21  ( 36 %) 6 (13.9%) 
LOW RISK 16  (28%) 36  (83.7%) 
TOTAL 57 43 
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TABLE : 5   
 
NAFLD SCORE 
 
AGE 1 2 3 Total 
26 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
28 0 1 0 1 
Row% 0.00% 100.00% 0.00% 100.00% 
Col% 0.00% 4.00% 0.00% 1.00% 
29 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
32 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
33 0 1 0 1 
Row% 0.00% 100.00% 0.00% 100.00% 
Col% 0.00% 4.00% 0.00% 1.00% 
35 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
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36 0 1 1 2 
Row% 0.00% 50.00% 50.00% 100.00% 
Col% 0.00% 4.00% 1.85% 2.00% 
38 1 0 1 2 
Row% 50.00% 0.00% 50.00% 100.00% 
Col% 4.76% 0.00% 1.85% 2.00% 
39 1 0 1 2 
Row% 50.00% 0.00% 50.00% 100.00% 
Col% 4.76% 0.00% 1.85% 2.00% 
40 2 2 1 5 
Row% 40.00% 40.00% 20.00% 100.00% 
Col% 9.52% 8.00% 1.85% 5.00% 
41 0 1 3 4 
Row% 0.00% 25.00% 75.00% 100.00% 
Col% 0.00% 4.00% 5.56% 4.00% 
42 1 0 0 1 
Row% 100.00% 0.00% 0.00% 100.00% 
Col% 4.76% 0.00% 0.00% 1.00% 
44 1 2 2 5 
Row% 20.00% 40.00% 40.00% 100.00% 
Col% 4.76% 8.00% 3.70% 5.00% 
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45 2 2 2 6 
Row% 33.33% 33.33% 33.33% 100.00% 
Col% 9.52% 8.00% 3.70% 6.00% 
46 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
47 0 0 6 6 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 11.11% 6.00% 
48 1 1 1 3 
Row% 33.33% 33.33% 33.33% 100.00% 
Col% 4.76% 4.00% 1.85% 3.00% 
49 0 0 4 4 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 7.41% 4.00% 
50 2 3 1 6 
Row% 33.33% 50.00% 16.67% 100.00% 
Col% 9.52% 12.00% 1.85% 6.00% 
51 0 0 2 2 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 3.70% 2.00% 
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52 1 1 2 4 
Row% 25.00% 25.00% 50.00% 100.00% 
Col% 4.76% 4.00% 3.70% 4.00% 
53 0 0 3 3 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 5.56% 3.00% 
54 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
55 0 2 0 2 
Row% 0.00% 100.00% 0.00% 100.00% 
Col% 0.00% 8.00% 0.00% 2.00% 
56 1 1 2 4 
Row% 25.00% 25.00% 50.00% 100.00% 
Col% 4.76% 4.00% 3.70% 4.00% 
57 1 0 1 2 
Row% 50.00% 0.00% 50.00% 100.00% 
Col% 4.76% 0.00% 1.85% 2.00% 
58 2 0 2 4 
Row% 50.00% 0.00% 50.00% 100.00% 
Col% 9.52% 0.00% 3.70% 4.00% 
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59 2 1 1 4 
Row% 50.00% 25.00% 25.00% 100.00% 
Col% 9.52% 4.00% 1.85% 4.00% 
60 0 2 3 5 
Row% 0.00% 40.00% 60.00% 100.00% 
Col% 0.00% 8.00% 5.56% 5.00% 
61 2 0 1 3 
Row% 66.67% 0.00% 33.33% 100.00% 
Col% 9.52% 0.00% 1.85% 3.00% 
64 0 0 2 2 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 3.70% 2.00% 
65 0 1 1 2 
Row% 0.00% 50.00% 50.00% 100.00% 
Col% 0.00% 4.00% 1.85% 2.00% 
67 0 1 0 1 
Row% 0.00% 100.00% 0.00% 100.00% 
Col% 0.00% 4.00% 0.00% 1.00% 
68 0 0 2 2 
Row% 0.00% 0.00% 100.00% 100.00% 
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Col% 0.00% 0.00% 3.70% 2.00% 
70 1 1 1 3 
Row% 33.33% 33.33% 33.33% 100.00% 
Col% 4.76% 4.00% 1.85% 3.00% 
71 0 1 0 1 
Row% 0.00% 100.00% 0.00% 100.00% 
Col% 0.00% 4.00% 0.00% 1.00% 
72 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
74 0 0 1 1 
Row% 0.00% 0.00% 100.00% 100.00% 
Col% 0.00% 0.00% 1.85% 1.00% 
TOTAL 21 25 54 100 
Row% 21.00% 25.00% 54.00% 100.00% 
Col% 100.00% 100.00% 100.00% 100.00% 
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FREQUENCY TABLES 
TABLE : 6 
 
 
Frequency Percent 
 Obese 57 57.0 
Non Obese 43 43.0 
Total 100 100.0 
 
 
 
TABLE : 7 
USG 
 
Frequency Percent 
 Fatty Liver 37 37.0 
Non Fatty liver 63 63.0 
Total 100 100.0 
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FREQUENCY TABLES 
TABLE : 8 
 
NAFLD SCORE 
 
Frequency Percent 
 High risk 21 21.0 
Intermediate risk 25 25.0 
Low risk 54 54.0 
Total 100 100.0 
 
 
TABLE : 9 
FIBRO SCAN 
 
Frequency 
Valid 
Percent 
 F0 - F1 5 23.8 
F2 - F3 13 61.9 
F4 3 14.3 
Total 21 100.0 
Total 100  
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TABLE 10 
NAFLD SCORE * FIBRO SCAN Crosstabulation 
 
  
FIBRO SCAN 
Total 
    F0 - F1 F2 - F3 F4 
NAFLD 
SCORE 
High risk 5 13 3 21 
Total 5 13 3 21 
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CONCLUSION 
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9.CONCLUSION 
NAFLD is an increasingly important chronic liver disease next to 
alcoholic liver disease ranging from Steatosis,steatohepatitis to cirrhosis. 
Insulin resistance and oxidativestress play important roles in 
etiopathogenesis  of non alcoholic liver disease. NAFLD is usually  
asymptomatic and  incidentally diagnosed  on routine laboratory 
investigation. Liver biopsy remains the most sensitive and specific means 
of providing prognostic information but nowadays other noninvasive tests 
are  upcoming and playing a major role in clinical practise. In the absence 
of definite  therapies, treatment is generally directed at optimizingbody 
weight and controlling risk factors. Liver transplantation is a therapeutic 
option for decompensated chronicliver disease. 
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ANNEXURE - I 
MASTER CHART 
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MASTER CHART 
S.NO NAME AGE SEX BMI USG 
NAFL
D 
SCOR
E 
FIBRO  
SCAN 
1 Amutha 58 2 1 1 1 3 
2 Sivagami 50 2 2 1 2   
3 Muniammal 50 2 1 2 2   
4 Shanthi 48 2 1 2 2   
5 Razia 47 2 2 2 3   
6 Bhagyam 61 2 1 1 1 2 
7 Krishnaveni 60 2 2 2 3   
8 Sherifa 49 2 2 2 3   
9 Maheshwari 50 2 1 1 1 2 
10 
Kousia 
Begum 44 2 1 2 3   
11 Sujatha 38 2 2 2 3   
12 Beevi john 70 2 1 1 2   
13 Kala 35 2 2 2 3   
14 Elizabeth 40 2 1 1 1 2 
15 Mani 60 1 1 2 3   
16 arumugam 70 1 2 1 1 1 
17 narayanan 64 1 2 2 3   
18 shanmugam 60 1 1 1 2   
19 thiyagarajan 59 1 1 1 1 2 
20 vasudevan 49 1 2 2 3   
21 robert 71 1 1 1 2   
22 bhoopalan 44 1 2 2 2   
23 srinivasan 61 1 1 1 1 2 
24 pachiappan 45 1 2 2 3   
25 anand 49 1 1 2 3   
26 rajendiran 47 1 2 2 3   
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27 Kuppu 40 2 1 1 1 2 
28 suseela devi 58 2 2 2 3   
29 arun 28 1 1 1 2   
30 chinnaponnu 65 2 1 2 2   
31 nagaraj 39 1 1 1 1 2 
32 krishnan 56 1 1 1 1 3 
33 mahalakshmi 44 2 2 2 3   
34 ahmed 52 1 1 2 3   
35 vasanthi 53 2 2 2 3   
36 raman 44 1 1 1 2   
37 meenal 36 2 2 2 2   
38 selvi 47 2 2 2 3   
39 asirvatham 48 1 1 2 3   
40 balaraman 65 1 2 2 3   
41 logeshwari 39 2 2 2 3   
42 sarawathy 56 2 1 2 3   
43 vasuki 48 2 1 1 1 2 
44 sukuna 51 2 1 2 3   
45 nagaraj 41 1 2 2 3   
46 selvam 50 1 2 2 3   
47 udaiyappan 41 1 1 1 2   
48 padmavathy 70 2 2 2 3   
49 rajeshwari 58 2 1 2 3   
50 valli 54 2 2 2 3   
51 kamalam 55 2 1 1 2   
52 selvi 47 2 2 2 3   
53 meenambal 60 2 2 2 2   
54 amudha 40 2 1 1 2   
55 mariammal 45 2 1 2 3   
56 devaki 52 2 2 2 3   
57 jothi 42 2 1 1 1 2 
58 chellammal 61 2 2 2 3   
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59 kuppuraj 49 1 2 2 3   
60 rajan 45 1 1 1 2   
61 kannan 51 1 1 2 3   
62 
krishnamoort
hy 57 1 1 1 1 2 
63 mariappan  64 1 2 2 3   
64 janaki 68 2 2 2 3   
65 perumal 56 1 1 2 3   
66 damodharan 72 1 2 2 3   
67 deivanai 74 2 2 2 3   
68 sarasu 58 2 1 1 1 2 
69 kothaiaamal 68 2 2 2 3   
70 nancy 33 2 1 2 2   
71 kayalvizhi 44 2 1 1 1 1 
72 kaniappan 56 1 1 1 2   
73 nivedha 29 2 2 2 3   
74 divya 38 2 1 1 1 1 
75 mohan 53 1 1 2 3   
76 monisha 26 2 2 2 3   
77 murugan 45 1 1 1 1 1 
78 govindammal 45 2 1 1 2   
79 rosammal 59 2 1 1 2   
80 pappu 50 2 2 2 2   
81 
krishnamoort
hy 41 1 2 2 3   
82 devi 50 2 1 1 1 2 
83 kannan 36 1 1 2 3   
84 valliyammal 53 2 2 2 3   
85 rajan 59 1 1 1 1 3 
86 sumathy 40 2 1 2 3   
87 murali 47 1 2 2 3   
88 senthil 52 1 1 1 1 2 
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89 kanchana 45 2 1 1 1 1 
90 priya 32 2 2 2 3   
91 ramasamy 40 1 1 1 2   
92 neelakandan 47 1 1 2 3   
93 joselin 41 2 1 2 3   
94 monica 55 2 2 1 2   
95 
ayesha 
begum 67 2 1 2 2   
96 thamaraiselvi 60 2 1 2 3   
97 
ramachandra
n 59 1 1 2 3   
98 ponni 46 2 2 2 3   
99 megala 52 2 1 1 2   
100 vimala 57 2 2 2 3   
      SEX BMI USG   
NAFLD 
SCORE 
      
MALE-
1 
0BES
E-1 
FATT
Y 
LIVE
R-1   HIGH RISK-1 
      
FEMAL
E-2 
NON-
OBES
E-2 
NO 
FATT
Y 
LIVE
R-2   
INTERMEDI
ATE RISK-2 
              LOW RISK-3 
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PROFORMA 
 
1. NAME: 
 
2. AGE: 
 
 
3. SEX: 
 
4. BMI: 
 
5. DIABETES MELLITUS: 
 
 
6. PLATELET COUNT: 
 
7. ASPARTATE TRANSAMINASE: 
 
8. ALANINE TRANSAMINASE: 
 
 
9. SERUM ALBUMIN: 
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10. FORMULA: 
 
-1.675+ 0.037 * AGE (years) +0.094 * BMI (kg/m2) +1.13 * IFG/ 
DIABETES ( yes =1,no=0) +0.99 * AST/ALT ratio -0.013 * platelet (* 
109 /l) -0.66 * albumin (g/dl). 
10. ULTRASOUND: 
           FATTY LIVER- YES/NO 
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